Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

Published:2019-08 Issue:4 Volume:19 Page:268-277.e1
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Yardley Denise A.,Hart Lowell,Favret Anne,Blau Sibel,Diab Sami,Richards Donald,Sparano Joseph^ORCID,Beck J. Thad,Richards Paul,Ward Patrick,Ramaswamy Bhuvaneswari,Tsai Michaela,Blackwell Kimberly,Pluard Timothy,Tolaney Sara M.,Esteva Francisco J.,Truica Cristina I.,Alemany Carlos,Volas-Redd Gena,Shtivelband Mikhail,Purkayastha Das,Dalal Anand A.,Miller Michelle,Hortobagyi Gabriel N.

Funder

Novartis Pharmaceuticals Corporation

AbbVie

Amgen

Astellas

AstraZeneca

Bayer

Biomarin

Biothera Pharmaceuticals

Bristol-Myers Squibb

Celgene

Celldex

Concordia

Eli Lilly

Eisai

Exelixis

G1 Therapeutics

Genzyme

GlaxoSmithKline

Imclone

Incyte

Ipsen Pharmaceuticals

Janssen

MedImmune

Medivation

Merck

Merrimack Pharmaceuticals

Novartis

Pfizer

Sanofi

Spectrum Pharmaceuticals

Tesaro

PreCOG

LLC

Genentech

Nektar

Eli Lilly and Company

Bristol-Meyers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Estimation of the number of women living with metastatic breast cancer in the United States;Mariotto;Cancer Epidemiol Biomarkers Prev,2017

2. Goals and objectives in the management of metastatic breast cancer;Chung;Oncologist,2003

3. Goals of treatment for patients with metastatic breast cancer;Smith;Semin Oncol,2006

4. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline;Rugo;J Clin Oncol,2016

5. Phase III study of letrozole vs. tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21

2. An integrated approach to understand the regulatory role of miR-27 family in breast cancer metastasis;BioSystems;2024-04

3. Updated Review Article: Cyclin-Dependent Kinase 4/6 Inhibitor Impact, FDA Approval, and Resistance Pathways;Journal of Pharmacy Technology;2023-10-24

4. Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer;American Society of Clinical Oncology Educational Book;2023-06

5. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review;ESMO Open;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3